Danish Healthtech Stock News

Earlier in 2025, ROCKWOOL A/S launched a share buy-back programme running from 7 February 2025 to 5 February 2026, authorising repurchases of up to €150 million and bringing its holding to 4,364,356 B shares, or 2.06% of total share capital. This sizeable, year-long repurchase plan highlights management’s commitment to returning capital to investors and adjusting the company’s share count over time. Now, we’ll examine how this sizeable buy-back programme interacts with Rockwool’s existing...

If you are wondering whether Genmab is still a smart buy after its big run or if most of the upside is already priced in, this breakdown will help you assess whether the current share price reflects its long term potential. The stock is up 31.6% year to date and 40.1% over the last year, despite only modest moves of 2.5% over 30 days and a slight 0.8% dip in the last week. This suggests sentiment has improved even though the longer 3 and 5 year returns are still negative. Recently, Genmab...

UIE Plc has commenced two parallel share repurchase programmes authorised at its May 2025 AGM, allowing buybacks of up to 5% of issued share capital overall and up to 2% via a Safe Harbour programme capped at DKK 245,000,000, alongside past declarations of both regular and special cash dividends of DKK 3.30 each with an ex-dividend date of 3 December 2025. Together, the capital return through dividends and the intention to cancel repurchased shares signal a clear focus on shrinking the...

On 5 February 2025, Pandora announced a new share buyback programme, appointing Danske Bank as sole lead manager for a tranche running until 30 January 2026, with the dual aim of reducing share capital and meeting obligations under company incentive schemes. This renewed focus on returning capital while supporting employee incentives adds a capital-allocation angle to Pandora's brand and margin-focused transformation story. We’ll now examine how Pandora’s decision to shrink its share capital...

Zealand Pharma (CPSE:ZEAL) just doubled down on its obesity and metabolic health ambitions by unveiling its Metabolic Frontier 2030 roadmap alongside a new multi program collaboration with OTR Therapeutics on next generation metabolic drugs. See our latest analysis for Zealand Pharma. Those moves land against a backdrop where the share price has climbed roughly 25% over the last three months but still sits well below earlier levels, and the three year total shareholder return above 150%...

FLSmidth (CPSE:FLS) climbed after ABG Sundal Collier lifted its rating to buy, highlighting expectations of healthier orders as metal prices rise and as the group moves beyond a restructuring phase. See our latest analysis for FLSmidth. The upgrade adds to a year where FLSmidth’s share price has delivered a solid year to date gain despite a softer 30 day share price return, while the three year total shareholder return nearly doubles investors’ money and signals that momentum is broadly...

Danske Bank (CPSE:DANSKE) has been in focus after launching a DKK 5 billion share buyback programme running through January 2026, a move that reduces the number of shares outstanding and returns excess capital to shareholders. See our latest analysis for Danske Bank. The DKK 5 billion buyback comes on top of already strong price momentum, with a roughly 53% year to date share price return and a three year total shareholder return near 190%, suggesting investors see improving fundamentals...

Earlier in 2025, Jyske Bank launched a share repurchase programme running from 26 February 2025 to 30 January 2026, targeting up to DKK 2.25 billion of stock, leaving it with 2,836,419 treasury shares or 4.61% of its share capital after recent purchases. The programme underlines management’s willingness to return excess capital to shareholders while potentially enhancing earnings per share through a lower share count. We’ll now explore how this sizeable buyback plan could reshape Jyske...

Rockwool (CPSE:ROCK B) just kicked off a year long share buy back programme of up to 150 million euros. This move typically signals management confidence and can quietly reshape the stock’s risk reward profile. See our latest analysis for Rockwool. The buy back lands after a choppy stretch, with a 1 month share price return of 5.95 percent, a year to date share price decline of 14.27 percent, and a still impressive 3 year total shareholder return of 50.26 percent. This suggests longer term...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

In recent months, DSV has expanded its electric truck fleet through a Volvo Trucks partnership in South Africa, completed the integration and go-live of its Dubai operations after absorbing Schenker, and participated as a Global Partner at the inaugural Automotive Logistics & Supply Chain ASEAN conference in Singapore to deepen its role in regional automotive supply chains. Together, these developments show DSV pushing harder into lower-emission transport, strengthening its Middle East...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Ambu fair value estimate is kr.130 Ambu's kr.85.60 share price...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Brd. Klee fair value estimate is kr.3,566 Current share price...

In late November 2025, Ørsted and other clean-energy groups won a US federal court ruling that declared President Donald Trump’s ban on new wind projects unlawful, removing a legal barrier to future developments. This decision not only supports Ørsted’s US offshore wind ambitions but also highlights how judicial outcomes can materially influence long-term project visibility and confidence. Next, we’ll examine how this court victory on the US wind project ban shapes Ørsted’s investment...

Earlier this month, Novo Nordisk presented topline phase 3 Evoke and Evoke+ results for oral semaglutide in Alzheimer’s disease, showing statistically significant but clinically modest biomarker reductions and no success on the primary endpoints, while also completing its US$5.20 billion acquisition of Akero Therapeutics and advancing multiple obesity-drug initiatives. Although the Alzheimer’s data fell short clinically, the biomarker insights, expanding obesity pipeline, and new...

A.P. Møller - Mærsk (CPSE:MAERSK B) has kicked off a sizeable DKK 14.4 billion share buy-back, with a fresh DKK 7.2 billion phase running into early 2026 and putting capital returns firmly in focus. See our latest analysis for A.P. Møller - Mærsk. The buy-back headlines land at a time when momentum is clearly picking up, with the 1 month share price return of 16.6 percent feeding into a robust 1 year total shareholder return of nearly 40 percent. This suggests confidence is rebuilding after a...

In recent months, Scandinavian Tobacco Group reported that its Signature Action cigarillo brand has almost doubled sales, added a new Signature Action Mix variant, and introduced larger 17-pack formats to appeal to value-focused smokers. The company has also moved into the nicotine pouch market with its XQS brand, which has quickly become the sixth-largest pouch label, signalling a meaningful broadening of its product portfolio beyond traditional tobacco. Next, we’ll examine how the rapid...

ALK-Abelló has announced that Edward Jordan, a biopharmaceutical executive with more than 30 years of experience, will become Executive Vice President and head of Commercial Operations in North America from January 2026, following the earlier elevation of the region into the Executive Leadership Team to support the Allergy+ strategy. By bringing in a leader with deep allergy and immunology expertise and a history of building US therapeutic markets, ALK-Abelló is clearly prioritizing stronger...

In early December 2025, Vestas reported a 10 MW order from Cementeria Costantinopoli in Italy and a separate undisclosed 660 MW order in EMEA, alongside a US court ruling that invalidated a Trump-era ban on new wind projects. Together, these developments highlight how improving policy clarity and direct industrial offtake projects can support Vestas’ role in supplying reliable on-site renewable power. We’ll now examine how the US court’s reversal of the wind project ban could reshape Vestas’...

Earlier this month, Genmab A/S completed a US$1.50 billion offering of 6.250% senior secured notes due 2032 and US$1.00 billion of 7.250% senior unsecured notes due 2033 to help finance its pending acquisition of Merus N.V., alongside new term loans and a revolving credit facility. The combination of large-scale debt financing and strong epcoritamab and EPKINLY clinical data across several lymphoma studies highlights how Genmab is using both capital structure and science to expand its...

Boehringer Ingelheim moving its partnered obesity drug candidate BI 3034701 into phase 2 trials puts fresh attention on Gubra (CPSE:GUBRA), as this step can influence future milestones and perceived pipeline value. See our latest analysis for Gubra. The move into phase 2 seems to have reignited interest in Gubra, with a 30 day share price return of 31.40 percent and a 90 day share price return of 29.59 percent, even though the year to date share price return is still negative and the 1 year...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

TORM plc ( CPH:TRMD A ) shareholders have seen the share price descend 13% over the month. But that scarcely detracts...